Literature DB >> 12429649

Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents.

Robert G Uzzo1, Paul Leavis, William Hatch, Vladimir L Gabai, Nickolai Dulin, Nadezhda Zvartau, Vladimir M Kolenko.   

Abstract

Prostate carcinogenesis involves transformation of zinc-accumulating normal epithelial cells to malignant cells, which do not accumulate zinc. In this study, we demonstrate by immunoblotting and immunohistochemistry that physiological levels of zinc inhibit activation of nuclear factor (NF)-kappa B transcription factor in PC-3 and DU-145 human prostate cancer cells, reduce expression of NF-kappa B-controlled antiapoptotic protein c-IAP2, and activate c-Jun NH(2)-terminal kinases. Preincubation of PC-3 cells with physiological concentrations of zinc sensitized tumor cells to tumor necrosis factor (TNF)-alpha, and paclitaxel mediated cell death as defined by terminal deoxynucleotidyl transferase-mediated nick end labeling assay. These results suggest one possible mechanism for the inhibitory effect of zinc on the development and progression of prostate malignancy and might have important consequences for the prevention and treatment of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429649

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  37 in total

1.  All-atom MD indicates ion-dependent behavior of therapeutic DNA polymer.

Authors:  Ryan L Melvin; William H Gmeiner; Freddie R Salsbury
Journal:  Phys Chem Chem Phys       Date:  2017-08-23       Impact factor: 3.676

2.  Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma.

Authors:  Leslie C Costello; Bernard A Levy; Mohamed M Desouki; Jing Zou; Omar Bagasra; Leslie A Johnson; Nader Hanna; Renty B Franklin
Journal:  Cancer Biol Ther       Date:  2011-08-15       Impact factor: 4.742

Review 3.  Metabolic targets for potential prostate cancer therapeutics.

Authors:  Jeffrey Twum-Ampofo; De-Xue Fu; Antonino Passaniti; Arif Hussain; M Minhaj Siddiqui
Journal:  Curr Opin Oncol       Date:  2016-05       Impact factor: 3.645

4.  All-Atom Molecular Dynamics Reveals Mechanism of Zinc Complexation with Therapeutic F10.

Authors:  Ryan L Melvin; William H Gmeiner; Freddie R Salsbury
Journal:  J Phys Chem B       Date:  2016-09-21       Impact factor: 2.991

5.  Resveratrol-zinc combination for prostate cancer management.

Authors:  Chandra K Singh; Anna Pitschmann; Nihal Ahmad
Journal:  Cell Cycle       Date:  2014-05-27       Impact factor: 4.534

Review 6.  Zinc in human health: effect of zinc on immune cells.

Authors:  Ananda S Prasad
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

7.  Predicting environmental chemical factors associated with disease-related gene expression data.

Authors:  Chirag J Patel; Atul J Butte
Journal:  BMC Med Genomics       Date:  2010-05-06       Impact factor: 3.063

8.  Cooperative stabilization of Zn(2+):DNA complexes through netropsin binding in the minor groove of FdU-substituted DNA.

Authors:  Supratim Ghosh; Freddie R Salsbury; David A Horita; William H Gmeiner
Journal:  J Biomol Struct Dyn       Date:  2012-11-16

Review 9.  Zinc and zinc transporters in prostate carcinogenesis.

Authors:  Vladimir Kolenko; Ervin Teper; Alexander Kutikov; Robert Uzzo
Journal:  Nat Rev Urol       Date:  2013-03-12       Impact factor: 14.432

10.  Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo.

Authors:  Konstantin Golovine; Peter Makhov; Robert G Uzzo; Tavis Shaw; David Kunkle; Vladimir M Kolenko
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.